Login / Signup

Folate levels in hepatocellular carcinoma patients with portal vein thrombosis.

Giulia MalaguarneraVito Emanuele CataniaSaverio LatteriAntonio Maria BorzìGaetano BertinoRoberto MadedduFilippo DragoMichele Malaguarnera
Published in: BMC gastroenterology (2020)
HCC patients with PVT showed lower levels of serum folate, respect HCC patients without PVT, with an average difference of 1.6 nmol/l p < 0.01 (95% CI - 2.54 to - 0.66), red cell folate 33.6 nmol/l p < 0.001 (95% CI - 43.64 to - 23.55) and albumin 0.29 g/dl p < 0.001 (95% CI - 0.42 to - 0.15); PVT patients displayed higher levels of bilirubin 0.53 mg/dl p < 0.001 (95% CI 0.23 to 0.78), INR 0.91 p < 0.001 (95% CI 0.72 to 1.09), γGT 7.9 IU/l (95% CI 4.14 to 11.65) and homocysteine 4.6 μmol/l p < 0.05 (95% CI 0.32 to 8.87) CONCLUSION: The low folate concentration and higher levels of homocysteine are associated with the loss of antithrombotic function, and with a more aggressive course of HCC and with a higher change of complications related to portal vein thrombosis.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • pulmonary embolism
  • peritoneal dialysis
  • atrial fibrillation
  • single cell
  • patient reported outcomes
  • cell therapy